FBIOP Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
$18,22
Cena · Sie 18, 2026
Dane fundamentalne na dzień Sie 13, 2026
Zakres 52 tyg.
$6–$21
79% of range
Ocena Analityków
BUY
8 analysts
Cena Docelowa
—
P/E (TTM)
-260.3
ROE
18.8%
Marża Zysku Netto
10.8%
O Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Przegląd firmy z Wikipedii
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.
Czytaj więcej
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.
History
The company was founded in 2006 under the name Coronado Biosciences, initially as an oncology company. In 2011, it was announced that Coronado raised $47.4 million in funding. Shortly thereafter it became a public company by registering all of its private shares as common stock. The company changed its name to Fortress Biotech in April 2015.
In November 2019, Fortress Biotech was ranked number 10 in the 2019 Deloitte Technology Fast 500 annual rankings.
Subsidiaries
Fortress Bio has 10 biopharmaceutical subsidiary companies which cover a range of medical therapy areas, including potential cancer treatments and therapies for rare diseases and conditions. These subsidiaries include Aevitas Therapeutics (formed in 2017), Avenue Therapeutics (formed in 2015), Caelum Biosciences (formed in 2017), Cellvation (formed in 2016), Checkpoint Therapeutics (formed in 2015), Cyprium Therapeutics (formed in 2017), Helocyte (formed in 2015), Journey Medical Corporation (formed in 2014), Mustang Bio (formed in 2015), Tamid Bio (formed in 2017) and Baergic Bio (formed in 2019).
Products
Fortress Bio’s marketed products are developed and commercialized by its subsidiary Journey Medical Corporation. These include Targadox tablets indicated for acne, eczema emollient Ceracade, wound cream Luxamend, topical corticosteroid Triderm, topical broad-spectrum antifungal solution Exelderm, Ala-Quin topical cream for skin conditions, and Ala-Scalp hydrocortisone lotion for skin conditions.
== References ==
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
FBIOP Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$18.22
Kapitalizacja Rynkowa
$571M
P/E (TTM)
-260.3
EPS (TTM)
$-0.07
Przychody (TTM)
$63M
Stopa dywidendy
0.11%
ROE
18.8%
D/E Dług/Kapitał
—
Zakres 52 tyg.
$6 – $21
FBIOP Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$63M
2021-12-31
→
2025-12-31
EPS
$-0.07
2021-12-31
→
2025-12-31
Wolny przepływ pieniężny
—
2021-12-31
→
2024-12-31
Marże
10.8%
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
FBIOP
Mediana porównawcza
P/E (TTM)
-260.3
28.5
P/S (TTM)
9.0
108.5
P/B
11.5
2.6
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
FBIOP
Mediana porównawcza
Operating Margin (Marża Operacyjna)
-111.0%
—
Net Profit Margin (Marża Zysku Netto)
10.8%
-2381.8%
ROA
4.1%
-60.0%
ROE
18.8%
-135.7%
ROIC
-138.2%
—
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
FBIOP
Mediana porównawcza
Current Ratio (Wskaźnik bieżący)
2.5
2.2
Quick Ratio (Wskaźnik Szybkości)
2.2
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
FBIOP
Mediana porównawcza
Revenue YoY (Przychody R/R)
9.7%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
-5.8%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
6.8%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
FBIOP
Mediana porównawcza
Payout Ratio (Wskaźnik Wypłaty Dywidendy)
9.7%
—
Dywidendy Stopa dywidendy, wskaźnik wypłaty, historia dywidend, 5-letni CAGR
Stopa Dywidendy
0.11%
Wskaźnik Wypłaty Dywidendy
9.7%
CAGR dywidendy 5-letni
—
| Data ex-dywidendy | Kwota |
|---|---|
| 14 czerwca 2024 | $0,1950 |
| 14 maja 2024 | $0,1950 |
| 12 kwietnia 2024 | $0,1950 |
| 14 marca 2024 | $0,1950 |
| 14 lutego 2024 | $0,1950 |
| 11 stycznia 2024 | $0,1950 |
| 14 grudnia 2023 | $0,1950 |
| 14 listopada 2023 | $0,1950 |
| 12 października 2023 | $0,1950 |
| 14 września 2023 | $0,1950 |
| 14 sierpnia 2023 | $0,1950 |
| 13 lipca 2023 | $0,1950 |
| 14 czerwca 2023 | $0,1950 |
| 12 maja 2023 | $0,1950 |
| 13 kwietnia 2023 | $0,1950 |
| 14 marca 2023 | $0,1950 |
| 14 lutego 2023 | $0,1950 |
| 12 stycznia 2023 | $0,1950 |
| 14 grudnia 2022 | $0,1950 |
| 14 listopada 2022 | $0,1950 |
FBIOP Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
8 analityków
- Mocne kupno 2 25,0%
- Kup 5 62,5%
- Trzymaj 1 12,5%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
-0.10%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 31 marca 2026 | $-1.13 | $-0.22 | -0.91% |
| 31 grudnia 2025 | $-0.01 | $0.11 | -0.12% |
| 30 września 2025 | $0.11 | $-0.43 | 0.54% |
| 30 czerwca 2025 | $-0.50 | $-0.37 | -0.13% |
| 31 marca 2025 | $-0.48 | $-0.50 | 0.02% |
| 31 grudnia 2024 | $-0.75 | $-0.77 | 0.02% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| FBIOP | $298M | -135.6 | 9.7% | 10.8% | 18.8% | — |
| INO | $120M | -1.0 | -70.0% | -130000.0% | -322.8% | — |
| ANIX | $136M | -12.1 | 0.00% | — | -62.2% | — |
| CADL | $310M | -7.8 | — | — | -53.7% | — |
| FBIO | — | — | — | — | — | — |
| BMEA | $90M | -1.1 | -67.1% | -3326.0% | -216.6% | — |
| GANX | $135M | -5.3 | -60.6% | — | -181.1% | — |
| ALDX | $312M | -9.2 | — | — | -68.0% | — |
| ICCC | — | -51.2 | 4.3% | — | — | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 17
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63M | $58M | $85M | $76M | $69M | $46M | $37M | $27M | $17M | $16M | $863.0K | $0 | |
| Cost of Revenue | $21M | $21M | $23M | $31M | $32M | $15M | $11M | $6M | $4M | $790.0K | $0 | · | |
| R&D Expense | · | · | $106M | $135M | $129M | $64M | $81M | $87M | $48M | $35M | $30M | $10M | |
| SG&A Expense | $96M | $88M | $91M | $114M | $87M | $61M | $56M | $53M | $51M | $28M | $19M | $10M | |
| Operating Expenses | $133M | $168M | $227M | $279M | $257M | $140M | $147M | $147M | $107M | $82M | $51M | $21M | |
| Operating Income | $-70M | $-110M | $-142M | $-204M | $-189M | $-94M | $-111M | $-120M | $-90M | $-66M | $-51M | $-21M | |
| Interest Expense | · | · | · | · | · | · | · | · | $6M | $4M | $1M | $1M | |
| Interest Income | $2M | $3M | $3M | $1M | $649.0K | $2M | $3M | $1M | $819.0K | $298.0K | $245.0K | $662.0K | |
| Other Non-op | $18M | $1M | $-3M | $1M | $24M | $-9M | $9M | $-11M | $-8M | $-6M | $-3M | $266.0K | |
| Pretax Income | $-34M | $-121M | $-154M | $-213M | $-164M | $-103M | $-102M | $-131M | $-98M | $-71M | $-54M | · | |
| Income Tax | $-620.0K | $312.0K | $521.0K | $449.0K | $500.0K | $500.0K | $0 | $0 | $2M | $0 | $0 | · | |
| Net Income | $7M | $-46M | $-61M | $-87M | $-65M | $-47M | $-40M | $-84M | $-67M | $-55M | $-48M | $-20M | |
| EPS (Basic) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 | · | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 | · | · | · | · | · | · | · | |
| Shares (Basic) | 27,901,889 | 20,784,334 | 8,110,906 | 5,924,967 | 81,700,220 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 27,901,889 | 20,784,334 | 8,110,906 | 5,924,967 | 81,700,220 | · | · | · | · | · | · | · | |
| EBITDA | $-70M | $-110M | $-142M | $-204M | $-189M | $-94M | $-111M | $-120M | $-100M | $-65M | $-51M | · |
Bilans 29
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $79M | $57M | $81M | $178M | $306M | $233M | $137M | $66M | $95M | $105M | $98M | $50M | |
| Short-term Investments | · | · | · | · | · | · | $0 | $18M | $36M | $0 | · | $20M | |
| Receivables | $30M | $10M | $15M | $28M | $23M | $24M | $14M | $5M | $8M | $2M | $0 | · | |
| Inventory | $10M | $14M | $10M | $14M | $10M | $1M | $857.0K | $678.0K | $171.0K | $203.0K | $0 | · | |
| Prepaid Expense | $5M | $7M | $10M | $10M | $7M | $7M | $4M | $7M | $6M | $9M | $2M | $702.0K | |
| Current Assets | $124M | $90M | $117M | $230M | $346M | $266M | $156M | $111M | $183M | $110M | $100M | $70M | |
| PP&E (Net) | $3M | $3M | $7M | $13M | $15M | $12M | $12M | $12M | $7M | $7M | $309.0K | $52.0K | |
| PP&E (Gross) | $8M | $15M | $15M | $25M | $24M | $19M | $17M | $15M | $8M | · | $377.0K | $94.0K | |
| Accum. Depreciation | $3M | $10M | $9M | $12M | $9M | $7M | $4M | $3M | $1M | · | $68.0K | $42.0K | |
| Goodwill | · | · | · | · | · | · | · | · | $19M | $19M | $0 | · | |
| Intangibles | $28M | $32M | $20M | $27M | $13M | $15M | $7M | $1M | $883.0K | $17M | $1M | $0 | |
| Other Non-current Assets | $401.0K | $731.0K | $4M | $973.0K | $1M | $1M | $1M | $276.0K | $258.0K | $394.0K | $43.0K | $64.0K | |
| Total Assets | $186M | $144M | $168M | $294M | $397M | $333M | $226M | $141M | $246M | $171M | $119M | $89M | |
| Accounts Payable | $14M | $32M | $35M | $57M | $47M | $11M | $35M | $34M | $27M | $2M | $10M | $366.0K | |
| Accrued Liabilities | $47M | $66M | $74M | $97M | $91M | $45M | $25M | $16M | $18M | $10M | $9M | $4M | |
| Short-term Debt | · | · | · | · | · | $0 | $7M | · | · | · | · | $0 | |
| Current Liabilities | $50M | $71M | $85M | $128M | $101M | $52M | $46M | $56M | $71M | $57M | $11M | $4M | |
| Capital Leases | $13M | $15M | $18M | $22M | $21M | $23M | $24M | $0 | · | · | · | · | |
| Deferred Tax | · | · | $233.0K | $0 | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $5M | $5M | $5M | $584.0K | $722.0K | |
| Total Liabilities | $123M | $146M | $166M | $244M | $171M | $136M | $154M | $121M | $125M | $88M | $34M | $19M | |
| Long-term Debt | $54M | $58M | $61M | $92M | $43M | $52M | $85M | $84M | $68M | $30M | $24M | $14M | |
| Total Debt | · | · | · | · | · | $0 | · | · | · | · | · | · | |
| Common Stock | $31.0K | $28.0K | $15.0K | $7.0K | $101.0K | $95.0K | $74.0K | $58.0K | $51.0K | $49.0K | $47.0K | $46.0K | |
| Paid-in Capital | $784M | $764M | $717M | $676M | $656M | $583M | $462M | $397M | $364M | $284M | $247M | $212M | |
| Retained Earnings | $-734M | $-741M | $-695M | $-634M | $-547M | $-483M | $-436M | $-396M | $-312M | $-245M | $-190M | $-142M | |
| Stockholders' Equity | $50M | $23M | $23M | $42M | $109M | $100M | $26M | $2M | $53M | $38M | $57M | $71M | |
| Liabilities + Equity | $186M | $144M | $168M | $294M | $397M | $333M | $226M | $141M | $246M | $171M | $119M | $89M | |
| Shares Outstanding | 31,364,094 | 27,908,839 | 15,093,053 | 7,366,283 | 101,435,505 | 94,877,492 | 74,027,425 | 57,845,447 | 50,991,285 | 48,932,023 | 47,147,032 | 46,494,034 |
Przepływy pieniężne 18
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | $1M | $944.0K | $26.0K | $23.0K | |
| Stock-based Comp | $29M | $33M | $17M | $23M | $19M | $13M | $13M | $15M | $13M | $12M | $14M | $6M | |
| Deferred Tax | · | · | · | · | · | · | · | $0 | $0 | $-73.0K | $0 | $0 | |
| Amort. of Intangibles | $4M | $3M | $4M | $4M | · | $1M | $1M | · | $2M | $0 | $0 | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | $-34M | $-4M | $14M | · | |
| Operating Cash Flow | $-66M | $-80M | $-128M | $-179M | $-117M | $-84M | $-95M | $-99M | $-81M | $-46M | $-20M | $-16M | |
| CapEx | · | $0 | $63.0K | $3M | $5M | $2M | $2M | $7M | $648.0K | $6M | $283.0K | $0 | |
| Investing Cash Flow | $10M | $-15M | $-2M | $-23M | $41M | $-7M | $20M | $19M | $-40M | $-6M | $8M | · | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Stock Issued | $1M | $4M | $2M | $6M | $9M | $46M | $21M | $10M | · | $0 | $0 | $4M | |
| Stock Repurchased | · | · | · | · | · | $70.0K | $0 | · | · | · | · | · | |
| Net Stock Activity | $1M | $4M | $2M | $6M | $9M | $47M | · | $10M | · | $0 | $0 | · | |
| Dividends Paid | $664.0K | $694.0K | $736.0K | $749.0K | $749.0K | $237.0K | $0 | · | · | · | · | · | |
| Financing Cash Flow | $77M | $71M | $33M | $75M | $149M | $172M | $147M | $51M | $150M | $43M | $61M | · | |
| Net Change in Cash | $22M | $-25M | $-98M | $-127M | $73M | $82M | $72M | $-29M | $29M | $-9M | $48M | $-50M | |
| Taxes Paid | $49.0K | $120.0K | $-55.0K | $858.0K | $993.0K | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-80M | $-128M | $-182M | $-121M | $-86M | $-97M | $-106M | $-88M | $-52M | $-21M | · | |
| Levered FCF | · | · | · | · | · | · | · | · | $-93M | · | · | · |
Rentowność 7
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -111.0% | -191.4% | -168.4% | -268.8% | -274.1% | -206.7% | -302.5% | -446.4% | -53.9% | -398.7% | -5855.3% | · | |
| Net Margin | 10.8% | -79.8% | -71.8% | -114.3% | -94.1% | -102.0% | -109.1% | -313.0% | -35.6% | -334.3% | -5611.6% | · | |
| Pretax Margin | -53.0% | -209.0% | -181.8% | -281.8% | -238.9% | -225.6% | -277.5% | -486.6% | -52.4% | · | · | · | |
| EBITDA Margin | -111.0% | -191.4% | -168.4% | -268.8% | -274.1% | -206.7% | -302.5% | -446.4% | -53.3% | -393.0% | -5852.3% | · | |
| ROA | 4.1% | -33.9% | -26.3% | -25.1% | -17.7% | -16.7% | -21.8% | -43.5% | -32.1% | -34.8% | -47.1% | · | |
| ROE | 18.8% | -203.2% | -188.7% | -115.1% | -61.9% | -73.5% | -284.8% | -309.2% | -146.9% | -115.6% | -76.0% | · | |
| ROIC | -138.2% | -486.7% | -633.5% | -488.9% | -174.0% | -94.1% | -422.7% | -6479.3% | -195.5% | · | · | · |
Płynność i wypłacalność 4
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.5 | 1.3 | 1.4 | 1.8 | 3.4 | 5.5 | 3.4 | 2.0 | 2.7 | 1.9 | 9.4 | · | |
| Quick Ratio | 2.2 | 0.9 | 1.1 | 1.6 | 3.3 | 5.3 | 3.3 | 1.6 | 2.3 | 1.6 | 9.3 | · | |
| Debt / Equity | · | · | · | · | · | 0.0 | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | -17.3 | -17.8 | -34.1 | · |
Efektywność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.9 | 0.1 | 0.0 | · | |
| Inventory Turnover | 1.7 | 1.7 | 2.2 | 2.6 | 5.7 | 12.9 | 13.7 | 14.4 | 19.6 | -7.8 | · | · | |
| Receivables Turnover | 3.2 | 4.5 | 3.9 | 3.0 | 2.9 | 2.8 | 3.8 | 4.1 | 39.1 | 18.0 | · | · |
Stopy Wzrostu 4
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 9.7% | -31.8% | 11.6% | 10.1% | 50.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -5.8% | -5.7% | 22.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 22.9% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 17
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $63M | $58M | $85M | $76M | $69M | $46M | $37M | $27M | $17M | $16M | $863.0K | $0 | |
| Net Income TTM | $7M | $-46M | $-61M | $-87M | $-65M | $-47M | $-40M | $-84M | $-67M | $-55M | $-48M | $-20M | |
| Market Cap | $298M | $186M | $179M | $1.95B | $2.63B | $1.84B | $1.52B | $832M | $1.16B | · | · | · | |
| Enterprise Value | · | · | · | · | · | $1.61B | · | · | · | · | · | · | |
| P/E | -135.6 | -2.5 | -1.4 | -1.1 | -32.8 | · | · | · | · | · | · | · | |
| P/S | 4.7 | 3.2 | 2.1 | 25.7 | 38.2 | 40.3 | 41.4 | 31.0 | 67.3 | · | · | · | |
| P/B | 6.0 | 8.2 | 7.9 | 46.7 | 24.2 | 18.3 | 57.8 | 449.4 | 22.1 | · | · | · | |
| P / Tangible Book | 13.4 | · | 79.4 | 134.3 | 27.3 | 21.5 | · | · | · | · | · | · | |
| P / Cash Flow | -4.5 | -2.3 | -1.4 | -10.9 | -22.5 | -22.0 | -16.0 | -8.4 | -13.6 | · | · | · | |
| P / FCF | · | -2.3 | -1.4 | -10.7 | -21.7 | -21.5 | -15.6 | -7.9 | -13.3 | · | · | · | |
| EV / EBITDA | · | · | · | · | · | -17.0 | · | · | · | · | · | · | |
| EV / FCF | · | · | · | · | · | -18.8 | · | · | · | · | · | · | |
| EV / Revenue | · | · | · | · | · | 35.2 | · | · | · | · | · | · | |
| Dividend Yield | 0.22% | 0.37% | 0.41% | 0.04% | 0.03% | 0.01% | 0.00% | · | · | · | · | · | |
| Earnings Yield | -0.74% | -40.5% | -71.4% | -90.5% | -3.0% | · | · | · | · | · | · | · | |
| Payout Ratio | 9.7% | -1.5% | -1.2% | -0.87% | -1.2% | -0.51% | · | · | · | · | · | · | |
| Annual Payout | $664.0K | $694.0K | $736.0K | $749.0K | $749.0K | $237.0K | $0 | · | · | · | · | · |
Rachunek zysków i strat 16
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19M | $16M | $16M | $18M | $16M | $13M | $15M | $15M | $15M | $13M | $20M | $35M | $17M | $12M | $16M | $17M | |
| Cost of Revenue | $6M | $6M | $5M | $6M | $5M | $5M | $5M | $4M | $6M | $6M | $2M | $6M | $8M | $6M | $8M | $7M | |
| R&D Expense | · | · | · | · | · | · | · | $9M | $13M | $25M | · | $20M | $32M | $40M | $35M | $30M | |
| SG&A Expense | $21M | $16M | $15M | $17M | $39M | $26M | $27M | $22M | $21M | $18M | $19M | $22M | $24M | $25M | $28M | $30M | |
| Operating Expenses | $29M | $24M | $21M | $24M | $53M | $35M | $39M | $37M | $43M | $50M | $40M | $49M | $67M | $71M | $71M | $67M | |
| Operating Income | $-10M | $-8M | $-5M | $-7M | $-36M | $-22M | $-24M | $-22M | $-28M | $-37M | $-20M | $-14M | $-50M | $-59M | $-55M | $-51M | |
| Interest Income | $2M | $570.0K | $637.0K | $736.0K | $622.0K | $490.0K | $527.0K | $589.0K | $734.0K | $833.0K | $705.0K | $547.0K | $715.0K | $1M | $687.0K | $419.0K | |
| Other Non-op | $11M | $1M | $-20.0K | $18M | $-62.0K | $-12.0K | $-14.0K | $1M | $282.0K | $-21.0K | $-5M | $620.0K | $395.0K | $304.0K | $6M | $648.0K | |
| Pretax Income | $922.0K | $142M | $-6M | $9M | $-12M | $-25M | $-26M | $-27M | · | · | $-29M | $-11M | · | · | $-57M | $-53M | |
| Income Tax | $320.0K | $5M | $-646.0K | $26.0K | $0 | $0 | $243.0K | $69.0K | $0 | $0 | $380.0K | $141.0K | $0 | $0 | $449.0K | $0 | |
| Net Income | $-468.0K | $110M | $-4M | $6M | $15M | $-11M | $-7M | $-13M | $-11M | $-15M | $-9M | $-5M | $-25M | $-22M | $-27M | $-23M | |
| EPS (Basic) | $-0.08 | $3.44 | $-0.22 | $0.13 | $0.50 | $-0.48 | $-0.16 | $-0.76 | $-0.73 | $-1.04 | $-0.41 | $-0.94 | $-3.65 | $-3.47 | $-11.39 | $-4.11 | |
| EPS (Diluted) | $-0.08 | $2.82 | $-0.15 | $0.11 | $0.45 | $-0.48 | $-0.16 | $-0.76 | $-0.73 | $-1.04 | $-3.67 | $-0.94 | $-3.65 | $-0.21 | $-11.42 | $-4.11 | |
| Shares (Basic) | 31,791,173 | 31,540,595 | -52,672,183 | 27,244,474 | 26,879,380 | 26,450,218 | -34,381,775 | 19,697,290 | 18,316,874 | 17,151,945 | -13,557,455 | 7,498,653 | 7,377,332 | 6,792,376 | -175,035,295 | 5,961,663 | |
| Shares (Diluted) | 31,791,173 | 38,412,716 | -61,473,472 | 33,100,961 | 29,824,182 | 26,450,218 | -34,381,775 | 19,697,290 | 18,316,874 | 17,151,945 | -108,650,727 | 7,498,653 | 7,377,332 | 101,885,648 | -175,035,295 | 5,961,663 | |
| EBITDA | $-10M | $-8M | · | $-7M | $-36M | $-22M | · | $-22M | $-28M | $-37M | · | $-14M | $-50M | $-59M | · | $-51M |
Bilans 27
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $197M | $256M | $79M | $86M | $74M | $91M | $57M | $59M | $76M | $84M | $81M | $72M | $78M | $152M | $178M | $208M | |
| Receivables | $36M | $25M | $30M | $18M | $16M | $18M | $10M | $11M | $10M | $10M | $15M | $8M | $17M | $28M | $28M | $29M | |
| Inventory | $8M | $9M | $10M | $12M | $13M | $12M | $14M | $12M | $10M | $11M | $10M | $11M | $12M | $13M | $14M | $15M | |
| Prepaid Expense | $4M | $5M | $5M | $2M | $7M | $5M | $7M | $3M | $5M | $12M | $10M | $6M | $7M | $8M | $10M | $6M | |
| Current Assets | $246M | $295M | $124M | $119M | $110M | $127M | $90M | $86M | $103M | $117M | $117M | $98M | $128M | $202M | $230M | $258M | |
| PP&E (Net) | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $6M | $7M | $7M | $7M | $12M | $13M | $14M | |
| PP&E (Gross) | $7M | $7M | $8M | $8M | $8M | $8M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $25M | $25M | $25M | |
| Accum. Depreciation | $3M | $2M | $3M | $3M | $3M | $3M | $10M | $12M | $10M | $9M | $9M | $9M | $8M | $13M | $12M | $12M | |
| Intangibles | $26M | $26M | $28M | $29M | $30M | $31M | $32M | $18M | $19M | $19M | $20M | $21M | $22M | $26M | $27M | $28M | |
| Other Non-current Assets | $1M | $740.0K | $401.0K | $18M | $3M | $3M | $731.0K | $3M | $3M | $4M | $4M | $5M | $4M | $943.0K | $973.0K | $1M | |
| Total Assets | $317M | $357M | $186M | $181M | $160M | $178M | $144M | $127M | $146M | $165M | $168M | $151M | $181M | $264M | $294M | $324M | |
| Accounts Payable | $12M | $14M | $14M | $19M | $20M | $28M | $32M | $34M | $38M | $42M | $35M | $45M | $49M | $66M | $57M | $56M | |
| Accrued Liabilities | $49M | $93M | $47M | $45M | $49M | $66M | $66M | $64M | $69M | $76M | $74M | $81M | $99M | $105M | $97M | $94M | |
| Short-term Debt | $5M | $2M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $62M | $103M | $50M | $54M | $58M | $74M | $71M | $70M | $76M | $88M | $85M | $97M | $129M | $129M | $128M | $106M | |
| Capital Leases | $11M | $12M | $13M | $13M | $13M | $14M | $15M | $15M | $16M | $18M | $18M | $19M | $20M | $21M | $22M | $21M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | |
| Other Non-current Liabilities | $3M | $2M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $111M | $154M | $123M | $116M | $123M | $146M | $146M | $140M | $160M | $169M | $166M | $164M | $197M | $244M | $244M | $222M | |
| Long-term Debt | $35M | $38M | $52M | $48M | $50M | $56M | $58M | $52M | $67M | $61M | $61M | $46M | $55M | $92M | $92M | $91M | |
| Total Debt | $5M | $2M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $33.0K | $33.0K | $31.0K | $31.0K | $30.0K | $30.0K | $28.0K | $28.0K | $23.0K | $19.0K | $15.0K | $9.0K | $132.0K | $130.0K | $7.0K | $108.0K | |
| Paid-in Capital | $788M | $786M | $784M | $786M | $780M | $774M | $764M | $755M | $739M | $733M | $717M | $702M | $699M | $693M | $676M | $669M | |
| Retained Earnings | $-624M | $-624M | $-734M | $-730M | $-736M | $-751M | $-741M | $-734M | $-721M | $-710M | $-695M | $-686M | $-681M | $-656M | $-634M | $-607M | |
| Stockholders' Equity | $164M | $162M | $50M | $56M | $44M | $22M | $23M | $21M | $18M | $23M | $23M | $17M | $19M | $38M | $42M | $62M | |
| Liabilities + Equity | $317M | $357M | $186M | $181M | $160M | $178M | $144M | $127M | $146M | $165M | $168M | $151M | $181M | $264M | $294M | $324M | |
| Shares Outstanding | 33,311,012 | 33,186,671 | 31,364,094 | 31,005,170 | 29,752,795 | 29,554,966 | 27,908,839 | 27,584,600 | 22,587,038 | 19,375,343 | 15,093,053 | 8,937,587 | 131,657,369 | 130,417,161 | 7,366,283 | 108,259,353 |
Przepływy pieniężne 12
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $3M | $2M | $2M | $3M | $17M | $6M | $16M | $7M | $5M | $5M | $4M | $4M | $4M | $5M | $6M | $7M | |
| Amort. of Intangibles | $969.0K | $1M | $1M | $1M | $1M | $1M | $982.0K | $814.0K | $814.0K | $814.0K | $815.0K | $814.0K | $1M | $1M | $1M | $1M | |
| Operating Cash Flow | $-59M | $204M | $-13M | $-6M | $-28M | $-20M | $-13M | $-20M | $-22M | $-25M | $-35M | $-17M | $-33M | $-43M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | $0 | · | · | $28.0K | $1.0K | $34.0K | $0 | $91.0K | $980.0K | |
| Investing Cash Flow | $-79.0K | $0 | $0 | $3M | $6M | $1M | $-15M | $0 | $0 | $0 | $-63.0K | $5M | $-2M | $-5M | $-391.0K | $-893.0K | |
| Stock Issued | · | $0 | $0 | $0 | $-1.0K | $1M | $340.0K | $568.0K | $2M | $894.0K | $-15.0K | $888.0K | $721.0K | $447.0K | $303.0K | $223.0K | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | $894.0K | · | · | · | $447.0K | · | · | |
| Dividends Paid | · | $0 | $166.0K | $166.0K | $166.0K | $166.0K | $166.0K | $176.0K | $176.0K | $176.0K | $180.0K | $185.0K | $185.0K | $186.0K | $186.0K | $188.0K | |
| Financing Cash Flow | $91.0K | $-27M | $6M | $15M | $5M | $52M | $26M | $3M | $14M | $28M | $44M | $-3M | $-30M | $22M | $19M | $4M | |
| Net Change in Cash | $-59M | $176M | $-7M | $12M | $-17M | $34M | $-2M | $-17M | $-8M | $2M | $9M | $-14M | $-66M | $-26M | $-30M | $-40M | |
| Taxes Paid | · | · | $0 | $0 | · | · | $5.0K | $0 | $115.0K | $0 | $-38.0K | $35.0K | $52.0K | $-104.0K | $-604.0K | $1M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | $-43M | · | · |
Rentowność 7
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -53.5% | -48.2% | · | -38.6% | -222.2% | -169.8% | · | -151.0% | -186.5% | -280.6% | · | -39.6% | -288.2% | -473.6% | · | -307.0% | |
| Net Margin | -2.5% | 688.2% | · | 33.2% | 94.3% | -80.5% | · | -88.0% | -73.5% | -118.3% | · | -14.5% | -142.5% | -173.3% | · | -136.2% | |
| Pretax Margin | 4.9% | 887.2% | · | 50.2% | · | · | · | -182.0% | · | · | · | -30.4% | · | · | · | · | |
| EBITDA Margin | -53.5% | -48.2% | · | -38.6% | -222.2% | -169.8% | · | -151.0% | -186.5% | -280.6% | · | -39.6% | -288.2% | -473.6% | · | -307.0% | |
| ROA | -0.20% | 41.3% | · | 3.8% | 10.1% | -6.2% | · | -9.3% | -6.7% | -7.2% | · | -2.1% | -9.1% | -6.4% | · | -6.2% | |
| ROE | -0.45% | 119.7% | · | 15.2% | 50.1% | -46.8% | · | -68.0% | -60.2% | -50.7% | · | -12.9% | -51.8% | -31.8% | · | -29.2% | |
| ROIC | -3.9% | -4.5% | · | -12.2% | · | · | · | -104.7% | · | · | · | -83.6% | · | · | · | · |
Płynność i wypłacalność 3
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.0 | 2.9 | · | 2.2 | 1.9 | 1.7 | · | 1.2 | 1.4 | 1.3 | · | 1.0 | 1.0 | 1.6 | · | 2.4 | |
| Quick Ratio | 3.8 | 2.7 | · | 1.9 | 1.6 | 1.5 | · | 1.0 | 1.1 | 1.1 | · | 0.8 | 0.7 | 1.4 | · | 2.2 | |
| Debt / Equity | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Efektywność 3
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.6 | 0.6 | · | 0.5 | 0.4 | 0.4 | · | 0.5 | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.4 | · | 0.5 | |
| Receivables Turnover | 0.7 | 0.7 | · | 1.2 | 1.3 | 0.9 | · | 1.6 | 1.1 | 0.7 | · | 1.9 | 0.8 | 0.4 | · | 0.5 |
Wycena (TTM) 14
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $69M | $63M | · | $62M | $59M | $56M | · | $77M | $80M | $78M | · | $81M | $65M | $72M | · | $80M | |
| Net Income TTM | $131M | $121M | · | $-2M | $-19M | $-50M | · | $-44M | $-56M | $-67M | · | $-74M | $-90M | $-81M | · | $-80M | |
| Market Cap | $670M | $462M | · | $285M | $229M | $178M | · | $150M | $359M | $322M | · | $105M | $2.30B | $2.40B | · | $2.03B | |
| Enterprise Value | $478M | $208M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 6.1 | 4.8 | · | -13.5 | -5.1 | -2.0 | · | -1.6 | -2.5 | -2.8 | · | -1.3 | -2.1 | -3.9 | · | -3.9 | |
| P/S | 9.7 | 7.3 | · | 4.6 | 3.9 | 3.2 | · | 1.9 | 4.5 | 4.1 | · | 1.3 | 35.3 | 33.4 | · | 25.3 | |
| P/B | 4.1 | 2.8 | · | 5.1 | 5.2 | 8.0 | · | 7.1 | 20.1 | 14.0 | · | 6.3 | 124.5 | 63.5 | · | 32.9 | |
| P / Tangible Book | 4.8 | 3.4 | · | 10.5 | 16.1 | · | · | 45.4 | · | 90.5 | · | · | · | 205.7 | · | 61.1 | |
| P / Cash Flow | · | 2.3 | · | · | · | -9.1 | · | · | · | -12.7 | · | · | · | -55.5 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | -55.5 | · | · | |
| EV / EBITDA | -47.8 | -26.9 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 6.9 | 3.3 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 16.4% | 20.8% | · | -7.4% | -19.7% | -50.1% | · | -63.7% | -40.0% | -35.2% | · | -76.0% | -47.0% | -25.9% | · | -25.6% | |
| Payout Ratio | · | 0.00% | · | · | · | -1.6% | · | · | · | -1.1% | · | · | · | -0.86% | · | · |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| Przychody | $63M | — | — | $58M | — |
| Marża Operacyjna % | -111.0% | — | — | -191.4% | — |
| Zysk netto | $7M | — | — | $-46M | — |
| Rozwodniony EPS | $-0.07 | — | — | $-2.69 | — |
Bilans
| 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 2.5 | — | — | 1.3 | — |
| Wskaźnik Szybkości | 2.2 | — | — | 0.9 | — |
Przepływy pieniężne
| 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | — | — | — | $-80M | — |
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Insiderzy spółki 1 insider · 1 dyrektorzy generalni · 0 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| David Jin | Chief Financial Officer | 22 czerwca 2026 A | 1 651 571 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 3 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Fortress Biotech, Inc. ×2 zgłoszenia | 3 stycznia 2025 | 12,40% | Aneks | — | SEC |
| Lindsay A Rosenwald, M.D. | 27 stycznia 2017 | — | Pierwotne zgłoszenie | — | SEC |
| Michael S. Weiss | 28 stycznia 2016 | — | Pierwotne zgłoszenie | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.